ViroMed today announced US FDA approval of a Phase I clinical trial for VM202 – ViroMed’s leading gene therapy treatment candidate for cardiovascular disease. This is the first ever US FDA approval for a Korean bioventure company.
ViroMed will conduct the clinical trial at the Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minnesota, with Dr. Timothy Henry as the Principal Investigator. Treatment will be directed at the restoration of blood flow to affected areas through regenerative angiogenesis. Clinical development of VM202 is also being carried out in Korea.
What is VM202
VM202 consists of ViroMed’s proprietary pCK vector encoding the genetically engineered hepatocyte growth factor (HGF) gene for the treatment of patients with ischemic disease, including coronary artery disease and peripheral artery disease. VM202 was engineered to express two isoforms of HGF protein in a highly efficient manner. Treatment is directed at restoration of blood flow to affected areas through regenerative angiogenesis.